Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Protein aids differential diagnosis in CLL

Pizzi M et al. Hum Pathol. 2018 Nov 17. doi: 10.1016/j.humpath.2018.10.038

Key clinical point: Cortactin expression may aid in the differential diagnosis of chronic lymphocytic leukemia from mantle cell lymphoma.

Major finding: Cortactin was expressed on 14 of 17 CLL samples vs. none of 16 MCL samples.

Study details: Immunohistochemistry analysis of samples from 131 patients with B-cell lineage non-Hodgkin lymphomas.

Disclosures: The study was internally supported. The authors reported having no conflicts of interest.

Read the article here.

Citation:

Pizzi M et al. Hum Pathol. 2018 Nov 17. doi: 10.1016/j.humpath.2018.10.038.

This Week's Must Reads

'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4

Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6

Must Reads in Aggressive Lymphomas

'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4

Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6